American society of clinical oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma

Journal of Clinical Oncology

Volumn 20, Issue 17, 2002, Pages 3719-3736

  Berenson, James R ^a   Hillner, Bruce E ^a   Kyle, Robert A ^a   Anderson, Ken ^a   Lipton, Allan ^a   Yee, Gary C ^a   Biermann, J Sybil ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CLOSTOBAN; ETIDRONIC ACID; IBANDRONIC ACID; LORON; PAMIDRONIC ACID; PLACEBO; TILUDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE DESTRUCTION; BONE DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; MEDICAL SOCIETY; MULTIPLE MYELOMA; OSTEOPENIA; PLASMACYTOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; VERTEBRA FRACTURE;

CLODRONIC ACID; DIPHOSPHONATES; DRUG MONITORING; HUMANS; IMIDAZOLES; MULTIPLE MYELOMA; OSTEOLYSIS;

EID: 0036729485     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.06.037     Document Type: Article

References (72)

1. Bone disease in multiple myeloma
2. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
3. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment
4. Multiple myeloma: Review of 869 cases
5. Solitary plasmacytoma of bone: Mayo Clinic experience
6. Localized and indolent myeloma
7. Monoclonal gammopathy of undetermined significance: Natural history in 241 cases
8. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer: American Society of Clinical Oncology Bisphosphonates Expert Panel
9. The periodic health examination: Canadian Task Force on the Periodic Health Examination
10. Rules of evidence and clinical recommendations on the use of antithrombotic agents
11. Rules of evidence and clinical recommendations on the use of antithrombotic agents
12. Bisphosphonates and breast carcinoma
13. Bisphosphonates
14. Treatment of cancer-associated hypercalcemia: Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone
15. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials
16. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone
17. Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group
18. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
19. Bisphosphonates: Mechanisms of action
20. Studies of the oral bioavailability of alendronate
21. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
22. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
23. Methodology for treatment evaluation in patients with cancer metastatic to bone
24. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases: Protocol 19 Aredia Breast Cancer Study Group
25. Counting recurrent events in cancer research
26. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
27. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma
28. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
29. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review
30. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma
31. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial
32. Measuring the quality of life of cancer patients: A concise QL-index for use by physicians
33. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial
34. Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma
35. Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma
36. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases
37. Effect of daily etidronate on the osteolysis of multiple myeloma
38. Treatment of multiple myeloma with etidronate: Results of a multicentre double-blind study - Groupe d'Etudes et de Recherches sur le Myelome (GERM)
39. Effects of intravenous ibandronate therapy on skeletal related events (SRE) and survival in patients with advanced multiple myeloma
40. The effect of long-term pamidronate treatment on skeletal morbidity in advanced multiple myeloma
41. Effect of pamidronate on skeletal morbidity in myelomatosis: Part 1. The results of the first 12 months of pamidronate therapy
42. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma
43. Oral bisphosphonates: A review of clinical use in patients with bone metastases
44. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate
45. Pamidronate: A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone
46. Treatment of postmenopausal osteoporosis
47. Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study - A randomized, controlled trial
48. Bisphosphonates in the treatment of malignant bone disease
49. Bisphosphonates as cancer drugs
50. Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: A prospective study of 87 bone biopsies
51. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
52. Effects of bone metastases on bone metabolism: Implications for diagnosis, imaging and assessment of response to cancer treatment
53. Markers of bone resorption in patients treated with pamidronate
54. Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma
55. Monitoring individual response to hormone replacement therapy with bone markers
56. Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma
57. Serum markers of bone metabolism in multiple myeloma: Prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP)
58. Current use of bisphosphonates in oncology
59. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer: A dose-seeking study
60. Pamidronate treatment in patients with malignant osteolytic bone disease and pain: A prospective randomized double-blind trial
61. Metastatic bone disease: A study of the surgical treatment of 166 pathologic humeral and femoral fractures
62. The final report of the expert panel for the radiation oncology bone metastasis work group of the American College of Radiology
63. A review of local radiotherapy in the treatment of bone metastases and cord compression
64. Strontium 89 therapy for the palliation of pain due to osseous metastases
65. Phase I-II study of 186 holmium-DOTP in combination with melphalan +/- total body irradiation (TBI) with autologous peripheral blood stem cell transplant (PBSCT) for patients with multiple myeloma
66. Economic impact of using clodronate in the management of patients with multiple myeloma
67. Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma
68. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease
69. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma